Sources: Redesign Health / ARC Global announcement, October 22, 2026 · ARC Global innovation model
Healthcare has no shortage of promising ideas that never make it beyond a pilot. Hospitals know where workflows fail, clinicians know which problems matter, and vendors have the technology to solve some of them. What is often missing is the machinery to turn those insights into scalable products—with health systems participating in the value. Redesign Health and ARC Global are joining forces around a different thesis: the hospital should be the place where healthcare companies are built, not merely where their products are sold.
On October 22, 2026, Redesign Health announced a merger with ARC Global, the healthcare innovation platform founded at Sheba Medical Center in Israel. The combined enterprise will embed engineering, AI, product development and company-building expertise alongside health-system teams to identify operational and clinical problems, develop technology, test it locally and commercialize successful solutions across a global network.
There is a significant third component: the organizations have agreed to acquire AVIA, subject to final approvals. AVIA brings U.S. health-system relationships and digital transformation intelligence to a structure already combining ARC's innovation network with Redesign's venture creation and applied technology capabilities. The AVIA acquisition is announced as pending, not completed.
The merger announcement does not disclose a purchase price, ownership splits, enterprise valuation, financing terms, a closing timetable for AVIA or standardized commercial economics for health-system partners. Those details will matter as much as the headline strategy.
The parties say their combined organizations work with more than 100 health systems across five continents; companies and products built through their networks have reached more than 100 million patients. These are aggregate company-reported network and reach metrics, not a count of live deployments of the new combined operating model or independently verified financial outcomes.
Each organization contributes a distinct part of the product-development problem.
| Organization | Core contribution | Why it matters |
|---|---|---|
| Redesign Health | AI engineering, venture creation, applied technology, investment and buyout strategies | Turns a validated problem into a product, operating team or company with capital and technical execution |
| ARC Global | Clinician-led innovation and health-system partnerships developed at Sheba Medical Center | Finds real workflow problems and provides clinical environments for practical development and validation |
| AVIA (pending acquisition) | Digital-health intelligence, vendor evaluation and transformation relationships among U.S. health systems | Can help identify repeatable institutional needs and inform evaluation, adoption and distribution across providers |
The distinctive proposition is not just access to hospitals. It's the combination of problem discovery, product engineering, capital formation, institutional implementation and commercial distribution. Most healthcare innovation models cover one or two of those steps. A platform that can genuinely close all five would reduce the friction between an internal operational idea and a product another hospital is willing to buy.
But an integrated platform also brings tension. The organizations may invest in or build companies while helping health systems evaluate technology. Maintaining credible, transparent vendor selection and an independent evidence standard will be important—particularly after AVIA's integration, given its advisory and solutions-intelligence role.
Many health systems have built innovation centers, accelerators and venture funds. Yet those activities often remain separate from day-to-day operations. A clinical team proposes a solution; innovation staff arrange a pilot; procurement evaluates the vendor; IT handles integration; finance tries to determine if the benefit was real. When a pilot ends, knowledge and momentum are easily lost.
The combined Redesign–ARC model proposes putting builders inside the institution rather than asking the institution to sponsor ideas developed exclusively elsewhere. The release says technologists, product leaders and AI researchers will work with frontline teams, IT organizations and internal developers. Solutions that succeed locally can then be deployed through participating peer organizations, with health systems sharing in the value they create.
That last clause changes the incentive. Instead of paying only for a vendor license, a participating hospital may be able to capture value from intellectual property, commercialization or company creation. The announcement does not define those ownership, licensing or revenue-share structures. It would be premature to assume every partner receives equity, a particular royalty or guaranteed financial upside.
The concept nonetheless addresses a real strategic frustration: health systems frequently supply the clinical context, implementation environment and operational insights that make health-tech products valuable, while much of the enterprise value accrues to external vendors and investors.
Healthcare innovation is shifting from hospitals as buyers to hospitals as co-builders and potential co-owners of technology. For the revenue cycle, that opens a path for providers to develop AI-native workflows around their own payer, billing and operational realities—then test whether those tools are useful across other systems.
The announcement describes an enterprise-wide health-system platform, not a dedicated revenue cycle launch. But RCM has several attributes that make it an appealing candidate for embedded venture creation. There are well-defined economic pain points, large administrative data sets, repeated workflows, fragmented payer interfaces and measurable financial outcomes. Operators can usually tell when a solution has improved net collections, staff capacity, days in A/R or preventable denials—assuming the measurement is designed correctly.
Consider where an internal team could identify a problem, co-develop a product and then validate it:
These are RCAI's illustrative opportunities, not products or client deployments identified in the announcement. A successful innovation platform should prove one real use case with a defined baseline before claiming repeatability across dozens of health systems.
The pending AVIA acquisition deserves attention beyond being a footnote to the merger. Redesign says AVIA's intelligence platform is used by more than 90,000 health-system leaders and staff to evaluate over 7,000 digital solutions. Those figures are company-provided usage and catalog metrics, not a census of active customers of the combined platform.
Combined with ARC's international network and Redesign's company-building operation, such a database could identify where institutions report similar problems, which categories are underserved and where existing products fall short. That could improve venture selection: instead of building another general-purpose AI assistant, the group could focus on problems that several health systems have confirmed they will prioritize.
It also raises a governance question. AVIA's value depends on being useful as an evaluator of available technology. If its owner also backs or develops competing products, vendor rankings, recommendation criteria and commercial conflicts need transparent safeguards. A hospital procurement committee should know when a recommended vendor is affiliated with the platform providing the advice.
The release describes a substantial operating footprint. ARC Global reports activity in 12 countries, 31 health systems and more than 300 hospitals, along with support for over 130 startups. It also cites a $6.7 billion portfolio value, over $1.5 billion raised and eight exits. Redesign Health separately says its portfolio companies have collectively raised more than $1.5 billion since its 2018 founding.
Those are different organizational measures and should not be added together as though they describe the new company's cash, assets or acquisition consideration. Likewise, the claimed 100-million-patient reach represents cumulative reach across network companies and products, not patients treated by a newly unified service.
The right measures going forward are less glamorous: how many products reach paid deployment, how long it takes to move from concept to rollout, how often solutions are adopted by a second or third institution, and whether operators can verify the claimed clinical or financial improvements.
Brett Shaheen, Redesign Health's CEO, will lead the combined company. Dr. Stephen Klasko, former CEO of Jefferson Health, has been named board chairman. Prof. Eyal Zimlichman, ARC Global's founder and president, is joining Redesign as vice chairman. Sheba Medical Center remains central to ARC's flagship innovation model.
The announced structure contains two distinct transactions: the Redesign–ARC merger and an agreement to acquire AVIA that remains subject to final approvals. Redesign also says it will continue venture capital and buyout investments. Those activities may complement the health-system development model, but investors and customers should ask how project opportunities are allocated among partner hospitals, Redesign funds and outside shareholders.
Neither the press release nor the cited organization descriptions provide the final cap table, transaction size, independent valuation or detailed IP agreement for participating health systems. A reader should not infer these economics from the combined companies' historical funding totals.
A solution that performs well at one health system can fail at another because of EHR configuration, patient population, payer mix, contracting, local staffing or workflows. For revenue cycle, payer-specific rules and account-level differences make that problem especially pronounced.
Creating a scalable product requires separating what is broadly repeatable from what is unique to the founding hospital. That means interoperable data models, configurable controls, observable outcomes, privacy and security safeguards, and a realistic support structure for new deployments. Without that foundation, venture creation can become custom consulting with a different label.
The combined platform's appeal is that its network may help test transferability earlier in development. But the release has not yet demonstrated a new product successfully deployed across the merged organizations' health-system network. That is the proof point RCAI will watch.
Redesign Health and ARC Global are proposing a new answer to a longstanding healthcare technology problem: the people who understand an operational failure are too often disconnected from the people with the capital and engineering resources to fix it. Their merger, coupled with the pending AVIA acquisition, brings the beginnings of a full institutional innovation stack under one structure.
For hospital revenue cycle teams, that could mean developing automation with the people closest to denials, authorizations, reimbursement and financial clearance—rather than adopting products designed around an idealized version of those workflows. The real differentiator would be proving outcomes at the founding institution and then replicating them elsewhere without recreating the entire solution.
The open questions are economic and operational: what hospitals own, whether recommendations remain independent, how capital is allocated, and whether this model can scale beyond bespoke projects. Those are not minor details. They determine whether the hospital truly becomes a venture partner or remains a customer inside a more elaborate sales process.
The next big shift in healthcare AI may not be which company builds the most agents. It may be who gets to build—and own—the businesses those agents make possible.
Independent analysis of healthcare AI, hospital revenue cycle operations, healthcare M&A and the economics of innovation.
Sources: Redesign Health and ARC Global merger announcement, PRNewswire, October 22, 2026; ARC Global innovation model and institutional network; Redesign Health operating model; AVIA. Historical reach, funding and portfolio figures are company-reported, and the AVIA transaction remains subject to approvals. Revenue cycle applications, deal interpretation and commercial diligence are independent RevCycleAI editorial analysis.